Lateral Epicondylitis(Tennis Elbow) - Pipeline Review, H1 2014

Lateral Epicondylitis(Tennis Elbow) - Pipeline Review, H1 2014

Summary

Global Markets Direct’s, ‘Lateral Epicondylitis(Tennis Elbow) - Pipeline Review, H1 2014’, provides an overview of the Lateral Epicondylitis(Tennis Elbow)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Lateral Epicondylitis(Tennis Elbow), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lateral Epicondylitis(Tennis Elbow) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Lateral Epicondylitis(Tennis Elbow)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Lateral Epicondylitis(Tennis Elbow) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Lateral Epicondylitis(Tennis Elbow) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Lateral Epicondylitis(Tennis Elbow) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Lateral Epicondylitis(Tennis Elbow)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Lateral Epicondylitis(Tennis Elbow) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Lateral Epicondylitis(Tennis Elbow) Overview 6
Therapeutics Development 7
Pipeline Products for Lateral Epicondylitis(Tennis Elbow) - Overview 7
Pipeline Products for Lateral Epicondylitis(Tennis Elbow) - Comparative Analysis 8
Lateral Epicondylitis(Tennis Elbow) - Therapeutics under Development by Companies 9
Lateral Epicondylitis(Tennis Elbow) - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Lateral Epicondylitis(Tennis Elbow) - Products under Development by Companies 13
Lateral Epicondylitis(Tennis Elbow) - Companies Involved in Therapeutics Development 14
Seikagaku Corporation 14
Chugai Pharmaceutical Co., Ltd. 15
Teikoku Pharma USA, Inc. 16
Molecular Pharmacology (USA) Limited 17
Kasiak Research Pvt. Ltd. 18
Lateral Epicondylitis(Tennis Elbow) - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
hyaluronate sodium - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
hyaluronate sodium - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
TPW-182 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Refaheal - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
RCT-01 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
MPLTL-100 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Lateral Epicondylitis(Tennis Elbow) - Recent Pipeline Updates 35
Lateral Epicondylitis(Tennis Elbow) - Dormant Projects 36
Lateral Epicondylitis(Tennis Elbow) - Product Development Milestones 37
Featured News & Press Releases 37
Nov 20, 2013: RepliCel Developing Phase II Trials for Regenerative Cell Therapy Technology 37
Appendix 38
Methodology 38
Coverage 38
Secondary Research 38
Primary Research 38
Expert Panel Validation 38
Contact Us 39
Disclaimer 39

List of Tables
Number of Products under Development for Lateral Epicondylitis(Tennis Elbow), H1 2014 7
Number of Products under Development for Lateral Epicondylitis(Tennis Elbow) - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 10
Comparative Analysis by Late Stage Development, H1 2014 11
Comparative Analysis by Clinical Stage Development, H1 2014 12
Products under Development by Companies, H1 2014 13
Lateral Epicondylitis(Tennis Elbow) - Pipeline by Seikagaku Corporation, H1 2014 14
Lateral Epicondylitis(Tennis Elbow) - Pipeline by Chugai Pharmaceutical Co., Ltd., H1 2014 15
Lateral Epicondylitis(Tennis Elbow) - Pipeline by Teikoku Pharma USA, Inc., H1 2014 16
Lateral Epicondylitis(Tennis Elbow) - Pipeline by Molecular Pharmacology (USA) Limited, H1 2014 17
Lateral Epicondylitis(Tennis Elbow) - Pipeline by Kasiak Research Pvt. Ltd., H1 2014 18
Assessment by Monotherapy Products, H1 2014 19
Number of Products by Stage and Target, H1 2014 21
Number of Products by Stage and Mechanism of Action, H1 2014 23
Number of Products by Stage and Route of Administration, H1 2014 25
Number of Products by Stage and Molecule Type, H1 2014 27
Lateral Epicondylitis(Tennis Elbow) Therapeutics - Recent Pipeline Updates, H1 2014 35
Lateral Epicondylitis(Tennis Elbow) - Dormant Projects, H1 2014 36

List of Figures
Number of Products under Development for Lateral Epicondylitis(Tennis Elbow), H1 2014 7
Number of Products under Development for Lateral Epicondylitis(Tennis Elbow) - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Clinical Stage Development, H1 2014 12
Assessment by Monotherapy Products, H1 2014 19
Number of Products by Top 10 Target, H1 2014 20
Number of Products by Stage and Top 10 Target, H1 2014 21
Number of Products by Top 10 Mechanism of Action, H1 2014 22
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 23
Number of Products by Top 10 Route of Administration, H1 2014 24
Number of Products by Stage and Top 10 Route of Administration, H1 2014 25
Number of Products by Top 10 Molecule Type, H1 2014 26
Number of Products by Stage and Top 10 Molecule Type, H1 2014 27